Bruneau N, St-Vil D, Luks F I, LaBerge J M, Bensoussan A L, Blanchard H
Hôpital Sainte-Justine, Montréal, Québec.
Ann Chir. 1993;47(9):803-9.
Tyrosinemia represents a very small percentage of patients undergoing liver transplantation world-wide. This disease is endemic within our referral area however, one-third of the liver transplantations at our institution are done for this disease. Since 1986, 16 patients with tyrosinemia and 34 patients with various other indications (non-tyrosinemic) have undergone a total of 55 liver transplantation. The survival rate for tyrosinemic patients is 87%, compared to 75% for non-tyrosinemic patients. Liver transplantation for hereditary tyrosinemia and other metabolic disorders without portal hypertension or previous portohepatic operations is notably easier to perform. Intraoperative blood loss was less, length of hospital stay was shorter and incidence of infections was lower in tyrosinemic than in non-tyrosinemic patients. Less than 10% of tyrosinemic patients had foci of hepatocellular carcinoma at the time of transplantation. For this reason, and while most patients with tyrosinemia will eventually require liver transplantation, our results do not support systematic early transplantation.
酪氨酸血症患者在全球接受肝移植的患者中占比极小。然而,在我们的转诊区域内,这种疾病较为常见,我院三分之一的肝移植手术都是针对该病进行的。自1986年以来,16例酪氨酸血症患者和34例有其他各种病症(非酪氨酸血症)的患者总共接受了55次肝移植手术。酪氨酸血症患者的生存率为87%,而非酪氨酸血症患者的生存率为75%。对于遗传性酪氨酸血症和其他无门静脉高压或既往门静脉肝门手术史的代谢紊乱疾病,进行肝移植手术明显更容易。与非酪氨酸血症患者相比,酪氨酸血症患者术中失血量更少,住院时间更短,感染发生率更低。不到10%的酪氨酸血症患者在移植时患有肝细胞癌病灶。因此,虽然大多数酪氨酸血症患者最终都需要进行肝移植,但我们的结果并不支持进行系统性早期移植。